blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3365336

EP3365336 - DEUTERATED COMPOUNDS FOR TREATING HEMATOLOGIC MALIGNANCIES, AND COMPOSITIONS AND METHODS THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.05.2024
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  23.06.2023
FormerGrant of patent is intended
Status updated on  20.02.2023
FormerExamination is in progress
Status updated on  06.03.2020
FormerRequest for examination was made
Status updated on  27.07.2018
FormerThe international publication has been made
Status updated on  28.04.2017
Most recent event   Tooltip12.07.2024Lapse of the patent in a contracting state
New state(s): IE		published on 14.08.2024 [2024/33]
Applicant(s)For all designated states
Neuform Pharmaceuticals, Inc.
1661 Worcester Road
Suite 102
Framingham, MA 01701 / US
[2018/35]
Inventor(s)01 / HUANG, Chaoran
92 West Pine Street
Auburndale, MA 02466 / US
02 / CHENG, Changfu
207 Howard Street
Northborough, MA 01532 / US
 [2018/35]
Representative(s)Bryers Intellectual Property Ltd
Bristol & Bath Science Park
Dirac Crescent, Emerson's Green
Bristol, BS16 7FR / GB
[N/P]
Former [2023/30]Bryers LLP
Bristol & Bath Science Park
Dirac Crescent, Emerson's Green
Bristol, BS16 7FR / GB
Former [2018/35]Bryers LLP
7 Gay Street
Bath, Bath and North East Somerset BA1 2PH / GB
Application number, filing date16857961.316.09.2016
[2018/35]
WO2016US52130
Priority number, dateUS201562244267P21.10.2015         Original published format: US 201562244267 P
[2018/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017069878
Date:27.04.2017
Language:EN
[2017/17]
Type: A1 Application with search report 
No.:EP3365336
Date:29.08.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 27.04.2017 takes the place of the publication of the European patent application.
[2018/35]
Type: B1 Patent specification 
No.:EP3365336
Date:26.07.2023
Language:EN
[2023/30]
Search report(s)International search report - published on:RU27.04.2017
(Supplementary) European search report - dispatched on:EP19.10.2018
ClassificationIPC:C07D401/14, C07D403/14, C07B59/00, A61P35/00, A61K31/53, A61K31/444, A61P35/02
[2023/11]
CPC:
C07D401/14 (EP,US); A61K31/444 (EP,US); A61K31/53 (EP,US);
A61P35/00 (EP); A61P35/02 (EP); C07B59/002 (EP,US);
C07D403/14 (EP,US); C07B2200/05 (EP,US) (-)
Former IPC [2018/47]C07D401/14, A61K31/444, A61K31/53, A61P35/00, C07B59/00, C07D403/14
Former IPC [2018/35]C07D401/14, A61K31/53, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/35]
Extension statesBA15.05.2018
ME15.05.2018
Validation statesMA15.05.2018
MD15.05.2018
TitleGerman:DEUTERIERTE VERBINDUNGEN ZUR BEHANDLUNG VON HÄMATOLOGISCHEN MALIGNEN, ZUSAMMENSETZUNGEN UND VERFAHREN DAFÜR[2018/35]
English:DEUTERATED COMPOUNDS FOR TREATING HEMATOLOGIC MALIGNANCIES, AND COMPOSITIONS AND METHODS THEREOF[2018/35]
French:COMPOSÉS DEUTÉRÉS POUR LE TRAITEMENT D'HÉMOPATHIES MALIGNES, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS[2018/35]
Entry into regional phase15.05.2018National basic fee paid 
15.05.2018Search fee paid 
15.05.2018Designation fee(s) paid 
15.05.2018Examination fee paid 
Examination procedure14.05.2018Date on which the examining division has become responsible
15.05.2018Examination requested  [2018/35]
16.05.2019Amendment by applicant (claims and/or description)
10.03.2020Despatch of a communication from the examining division (Time limit: M04)
17.07.2020Reply to a communication from the examining division
26.01.2021Despatch of a communication from the examining division (Time limit: M06)
02.08.2021Reply to a communication from the examining division
21.02.2023Communication of intention to grant the patent
21.06.2023Fee for grant paid
21.06.2023Fee for publishing/printing paid
21.06.2023Receipt of the translation of the claim(s)
Opposition(s)29.04.2024No opposition filed within time limit [2024/27]
Fees paidRenewal fee
06.09.2018Renewal fee patent year 03
19.09.2019Renewal fee patent year 04
25.09.2020Renewal fee patent year 05
16.09.2021Renewal fee patent year 06
20.09.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
ES26.07.2023
FI26.07.2023
HR26.07.2023
IT26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
IE16.09.2023
LU16.09.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
[2024/33]
Former [2024/28]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
ES26.07.2023
FI26.07.2023
HR26.07.2023
IT26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
LU16.09.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/26]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
ES26.07.2023
FI26.07.2023
HR26.07.2023
IT26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
LU16.09.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/25]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
ES26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
LU16.09.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/23]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
ES26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/22]AT26.07.2023
CZ26.07.2023
DK26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/20]AT26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RS26.07.2023
SE26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/10]AT26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RS26.07.2023
SE26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/09]AT26.07.2023
FI26.07.2023
LT26.07.2023
NL26.07.2023
SE26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
Former [2024/08]LT26.07.2023
NL26.07.2023
NO26.10.2023
GR27.10.2023
Former [2024/05]NL26.07.2023
Documents cited:Search[A]WO2015018060  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-14 * examples 24, 25 * * claims 1, 8 *;
 [A]  - ROBERT H. HOWLAND, "Deuterated Drugs", JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, US, (20150901), vol. 53, no. 9, doi:10.3928/02793695-20150821-55, ISSN 0279-3695, pages 13 - 16, XP055512787 [A] 1-14 * abstract * * page 15, column 3, paragraph 3 - page 16, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.3928/02793695-20150821-55
 [A]  - R. SHARMA ET AL, "Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs", DRUG METABOLISM AND DISPOSITION, (20120301), vol. 40, no. 3, doi:10.1124/dmd.111.042770, pages 625 - 634, XP055259415 [A] 1-14 * abstract * * page 625, column 1 * * page 633, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1124/dmd.111.042770
International search[A]WO2013102431  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-64 * , pages 46, 134, compound 409, claims *;
 [A]WO2015003355  (AGIOS PHARMACEUTICALS INC [US], et al) [A] 1-64* , examples, claims *;
 [A]WO2015017821  (AGIOS PHARMACEUTICALS INC [US]) [A] 1-64 * , examples claims *
by applicant   - BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - BUNDGARD, H., Design of Prodrugs, Elsevier, (19850000), pages 7 - 9,21-24
    - HIGUCHI, T. et al., Bioreversible Carriers in Drug Design, American Pharmaceutical Association, (19870000), vol. 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.